Meriofert Kit

Human luteinising hormone, the active ingredient in Meriofert Kit, is a gonadotropin presented as an injection for intramuscular or subcutaneous use. It is employed to treat infertility caused by anovulation and to support assisted reproductive technologies such as in vitro fertilisation.

GNH USA supplies Meriofert Kit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU manufacturing standards and provides cold‑chain logistics for biologic products.

Meriofert Kit, a gonadotropin preparation, is used in reproductive medicine to stimulate ovarian function. - Anovulatory infertility: promotes follicular development and ovulation in women who do not ovulate spontaneously. - In vitro fertilisation (IVF): supports controlled ovarian hyperstimulation to obtain multiple mature oocytes. - Ovarian hypogonadism: enhances estradiol production and follicle growth in patients with deficient endogenous gonadotropins.

Injection of Meriofert Kit may be associated with a range of adverse reactions.

Common Side Effects: - Injection site pain or bruising - Mild abdominal discomfort - Headache - Nausea or vomiting - Transient ovarian hyperstimulation (mild) - Transient fluid retention

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome - Thromboembolic events - Allergic reactions including anaphylaxis - Pulmonary edema - Multiple pregnancy - Ectopic pregnancy

Prior to initiating therapy, clinicians should consider several safety measures. - Monitor ovarian response: perform ultrasound and estradiol measurements during stimulation. - Assess for pregnancy: avoid use in confirmed pregnancy. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Use caution in thromboembolic disease: evaluate risk before therapy. - Do not combine with other gonadotropins unless directed: follow prescriber guidance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed before prescribing.

Major Interactions (Avoid): - Concurrent use with GnRH antagonists that suppress LH/FSH activity. - Co‑administration with high‑dose estrogen contraceptives that may blunt response. - Use with anticoagulants in patients at risk of ovarian hyperstimulation syndrome.

Moderate Interactions (Monitor Closely): - Oral estrogen therapy: may alter ovarian response, monitor estradiol levels. - Thyroid hormone replacement: can affect gonadotropin sensitivity, adjust dosing as needed. - Corticosteroids: may mask symptoms of hyperstimulation, observe closely. - Diuretics: may influence fluid balance during stimulation.